Disturbance of lysosomal glycogen metabolism by liposomal anti-alpha-glucosidase and some anti-inflammatory drugs.
The size-distribution of liver glycogen was shown to be distinctly affected by the anti-inflammatory drugs salicylate and indomethacin. By measurement of the incorporation of radioactive glucose into glycogen, salicylate was shown to have a depressing effect on overall liver glycogen metabolism. These effects appear to arise from the stabilizing of the lysosome by the drugs. The incorporation, via liposomes, of purified anti-1,4-alpha-glucosidase activity and in the content of high-molecular-weight  glycogen. These changes are increased by prolonged liposomal antibody treatment and suggest that a possible feedback control mechanism operates in the incorporation of glycogen into lysosomes. These experiments may be useful as a model of glycogen turnover and its failure in glycogenosis type II (Pompe's disease).
D020909:Acarbose; D000818:Animals; D000906:Antibodies / Q000276:immunology; D005947:Glucose / Q000378:metabolism; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D065089:Glycoside Hydrolase Inhibitors; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology*; D008081:Liposomes / Q000008:administration & dosage; D008112:Liver Glycogen / Q000378:metabolism*; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008970:Molecular Weight; D009844:Oligosaccharides / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012459:Salicylates / Q000494:pharmacology*; D020156:Salicylic Acid; D014312:Trisaccharides / Q000276:immunology / Q000494:pharmacology*
D000906:Antibodies; D065089:Glycoside Hydrolase Inhibitors; D008081:Liposomes; D008112:Liver Glycogen; D009844:Oligosaccharides; D012459:Salicylates; D014312:Trisaccharides; D005959:Glucosidases; D005947:Glucose; D020156:Salicylic Acid; D020909:Acarbose; D007213:Indomethacin